{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-007221","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.584001+00:00","generated_at":"2026-05-27T07:07:19.418295+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel Therapeutics shareholders approve reverse stock split range of 1:5 to 1:30","bullets":["Proposal 1 passed with ~90.8% of votes cast in favor (27.6M for, 2.5M against, 0.3M abstain).","Proposal 2 (adjournment) also approved with ~91.5% of votes cast in favor (27.7M for).","Board retains discretion to select exact split ratio between 1:5 and 1:30 at a later date.","Approximately 61.2% of outstanding common stock (30.4M shares) was represented at the special meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-007221","json":"https://secwatch.observer/filing/0001104659-25-007221.json","markdown":"https://secwatch.observer/filing/0001104659-25-007221.md","text":"https://secwatch.observer/filing/0001104659-25-007221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/0001104659-25-007221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/tm254832d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:07:19.418295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}